Oncology Biomarker Diagnostics: Where We Are, Where We Need To Be: Identifying cancer biomarkers that are clinically useful is difficult. So is obtaining funding to get biomarker diagnostics to market.
{"title":"Oncology Biomarker Diagnostics: Where We Are, Where We Need To Be: Identifying cancer biomarkers that are clinically useful is difficult. So is obtaining funding to get biomarker diagnostics to market.","authors":"Sarah Collins","doi":"","DOIUrl":null,"url":null,"abstract":"","PeriodicalId":89534,"journal":{"name":"Biotechnology healthcare","volume":"7 3","pages":"22-5"},"PeriodicalIF":0.0000,"publicationDate":"2010-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2957736/pdf/bh0703022.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Biotechnology healthcare","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}